Literature DB >> 19119537

HBeAg/anti-HBe, alanine aminotransferase and HBV DNA levels in HBsAg positive chronic carriers.

Fareha Jesmin Rabbi1, Md Kamar Rezwan, Tahmina Shirin.   

Abstract

Serum samples from a total of 72 chronic hepatitis B virus carriers were analysed by serological, biochemical and molecular assays. The aim was to evaluate the relationship of the serological and biochemical parameters with molecular markers in order to assess the infectivity of virus. Out of 72 chronic HBsAg positive carriers, 28 patients were HBeAg positive and anti-HBe negative, 38 patients were HBeAg negative and anti-HBe positive, only 3 patients were positive for both HBeAg and anti-HBe and the rest 3 patients were negative for both markers. Detectable HBV DNA lcvcl was found in 92.86% HBsAg-positive/anti-HBe negative patients along with raised alanine aminotransferase (ALT) level (67.86%) compared with HBeAg-negative/anti-HBe positive carriers (36.84%) (p value = 0.02) and out a total of 38 HBeAg-negative/anti-HBe positive carriers, 12 (31.58%) patients had detectable lcvel of HBV DNA. Among the 14 HBeAg-negative/anti-HBe positive patients with elevated ALT level, 8 (57.14%) had detectable HBV DNA whereas out of 24 HBeAg-negative/anti-HBe positive patients with normal ALT level only 4 (16.66%) had detectablc HBV DNA lcvel. Significantly high rate of detection of HBV DNA was seen among anti-HBe positive patients with raised ALT level compared with the patients with normal ALT level (p value = 0.01).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19119537     DOI: 10.3329/bmrcb.v34i2.1173

Source DB:  PubMed          Journal:  Bangladesh Med Res Counc Bull        ISSN: 0377-9238


  7 in total

1.  Serum HBeAg and HBV DNA levels are not always proportional and only high levels of HBeAg most likely correlate with high levels of HBV DNA: A community-based study.

Authors:  Ping Chen; Qinfen Xie; Xuan Lu; Chengbo Yu; Kaijin Xu; Bing Ruan; Hongcui Cao; Hainv Gao; Lanjuan Li
Journal:  Medicine (Baltimore)       Date:  2017-08       Impact factor: 1.889

2.   Evaluation of serum HBV viral load, transaminases and histological features in chronic HBeAg-negative hepatitis B patients.

Authors:  Abbas Esmaeelzadeh; Hassan Saadatnia; Bahram Memar; Elham Mokhtari Amirmajdi; Azita Ganji; Ladan Goshayeshi; Zahra Meshkat; Alireza Pasdar; Hassan Vosoughinia; Mohammadreza Farzanehfar; Shahrzad Tehranian; Kamran Ghaffarzadehgan; Farnood Rajabzadeh; Mitra Ahadi
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2017

3.  Serological and molecular characterization of hepatitis B virus in asymptomatic blood donors in Iran.

Authors:  Mona Seyed Attaran; Seyed Masoud Hosseini; Javad Fakhari; Zohreh Sharifi
Journal:  Iran J Microbiol       Date:  2018-02

4.  Serum miR-375 Levels Are Closely Related to Disease Progression from HBV Infection to HBV-Related Hepatocellular Carcinoma.

Authors:  Weilu Zhang; Ting Fu; Zhenjun Guo; Ye Zhang; Lei Zhang; Haixia Su; Yong Long; Zhaohua Ji; Yongping Yan; Zhongjun Shao
Journal:  Biomed Res Int       Date:  2020-04-20       Impact factor: 3.411

5.  Serolological Profile Among HBsAg-Positive Infections in Southeast China: A Community-Based Study.

Authors:  Ping Chen; Chengbo Yu; Wei Wu; Jinghua Wang; Bing Ruan; Jingjing Ren; Shigui Yang; Kaijin Xu; Liang Yu; Lanjuan Li
Journal:  Hepat Mon       Date:  2013-01-23       Impact factor: 0.660

6.  Consolidation period of 18 months no better at promoting off-treatment durability in HBeAg-positive chronic hepatitis B patients with tenofovir disoproxil fumarate treatment than a 12-month period: A prospective randomized cohort study.

Authors:  Chun-Hsiang Wang; Kuo-Kuan Chang; Ruey-Chang Lin; Ming-Jeng Kuo; Chi-Chieh Yang; Yuan-Tsung Tseng
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.817

7.  Estimating the proportion of people with chronic hepatitis B virus infection eligible for hepatitis B antiviral treatment worldwide: a systematic review and meta-analysis.

Authors:  Mingjuan Tan; Ajeet S Bhadoria; Fuqiang Cui; Alex Tan; Judith Van Holten; Philippa Easterbrook; Nathan Ford; Qin Han; Ying Lu; Marc Bulterys; Yvan Hutin
Journal:  Lancet Gastroenterol Hepatol       Date:  2020-11-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.